Startseite>>Signaling Pathways>> GPCR/G protein>> mGluR >>Foliglurax

Foliglurax (Synonyms: PXT002331)

Katalog-Nr.GC36064

Foliglurax (PXT002331) ist ein hochselektiver und potenter, das Gehirn durchdringender metabotroper Glutamatrezeptor 4 positiver allosterischer Modulator (mGluR4 PAM) mit einem EC50 von 79 nM.

Products are for research use only. Not for human use. We do not sell to patients.

Foliglurax Chemische Struktur

Cas No.: 1883329-51-8

Größe Preis Lagerbestand Menge
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Foliglurax (PXT002331) is a highly selective and potent, brain-penetrant metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) with an EC50 of 79 nM[1]. Antiparkinsonian effect[1]. mGlu4|79 nM (EC50)

Foliglurax, a highly selective and potent mGlu4 receptor PAM with a marked brain-penetrance feature, might revolutionize the field of mGlu4 receptor drug targeting in CNS disorders[2].

[1]. Charvin D, et al. Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4. J Med Chem. 2017 Oct 26;60(20):8515-8537. [2]. Volpi C, et al. Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4. Expert Opin Drug Discov. 2018 May;13(5):411-423.

Bewertungen

Review for Foliglurax

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Foliglurax

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.